Characteristics | < 1.7 g n = 204 | ≥1.7 g n = 217 | p-value |
---|---|---|---|
Daily intake of ω-3 at admission (g) | 1.0(0.7) | 2.7(1.3) | < 0.001 |
Daily intake of ω-3 at 3 months (g) | 1.1(0.9) | 1.9(1.5) | < 0.001 |
Age, (years) | 60 ± 10 | 58 ± 11 | 0.256 |
Gender: female n(%) | 52(26) | 52(24) | 0.717 |
Diabetes mellitus, n(%) | 31(15) | 55(25) | 0.010 |
Hypertension, n(%) | 113(56) | 141(65) | 0.044 |
Previous myocardial infarction, n(%) | 21(10) | 22(10) | 0.957 |
Previous stroke, n(%) | 11(5) | 11(5) | 0.881 |
Coronary reperfusion therapy, n(%) | 171(84) | 194(89) | 0.012 |
Percutaneous coronary intervention (PCI), n(%) | 94(46) | 100(46) | 0.479 |
Fibrinolytic therapy, n(%) | 125(61) | 151(70) | 0.052 |
PCI and fibrinolytic therapy, n(%) | 53(26) | 65(30) | 0.190 |
Current smoking, n(%) | 78(38) | 83(39) | 0.970 |
Ex smoking, n(%) | 59(29) | 70(33) | 0.440 |
Drugs previously in use: | |||
Statin, n(%) | 13(6) | 13(6) | 0.861 |
Calcium channel blocker, n(%) | 20(10) | 22(10) | 0.922 |
Beta-blocker, n(%) | 40(20) | 32(14) | 0.139 |
Angiotensin inhibitor drugs (ACEi or ARB), n(%) | 66(32) | 93(43) | 0.026 |
Aspirin, n(%) | 34(17) | 33(15) | 0.666 |
HbA1c, (%) | 6.0(0.8) | 6.1(1.2) | 0.830 |
Glomerular filtration rate, (mL/min) | 70(24) | 69(25) | 0.173 |
Triglycerides, (mg/dL) | 118(90) | 147(126) | 0.001 |
LDL-C, (mg/dL) | 118 ± 38 | 121 ± 48 | 0.538 |
HDL-C, (mg/dL) | 38(13) | 36(13) | 0.150 |
Systolic blood pressure, (mmHg) | 130(37) | 140(40) | 0.016 |
Diastolic blood pressure, (mmHg) | 80(30) | 85(26) | 0.063 |
Heart rate, (bpm) | 75(18) | 75(25) | 0.415 |
Time between MI onset and medical care, (minutes) | 120(255) | 90(182) | 0.126 |
Killip >I, n(%) | 20(10) | 26(12) | 0.470 |
Peak CK-MB, (UI/L) | 161(243) | 200(268) | 0.070 |
Troponin, (ng/mL) | 2.40(22.36) | 1.52(20.16) | 0.468 |
Body Mass Index, (kg/m2) | 25.9(5.1) | 26.8(5.0) | 0.234 |
Waist circumference, (cm) | |||
Female | 95(14) | 93(9) | 0.164 |
Male | 95(13) | 98(12) | 0.173 |